CeriBell (NASDAQ:CBLL) Receives Consensus Recommendation of “Buy” from Brokerages

CeriBell (NASDAQ:CBLL) has been assigned an average recommendation of “Buy” from the six analysts that are covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $32.60.

A number of equities analysts have recently commented on CBLL shares. William Blair started coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued an “outperform” rating on the stock. Canaccord Genuity Group assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $30.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on shares of CeriBell in a report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price target for the company. TD Cowen raised their price target on CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Finally, Canaccord Genuity Group boosted their price objective on CeriBell from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, December 9th.

Institutional Investors Weigh In On CeriBell

Hedge funds have recently made changes to their positions in the stock. PNC Financial Services Group Inc. bought a new position in CeriBell during the fourth quarter valued at about $47,000. Corebridge Financial Inc. bought a new stake in shares of CeriBell during the fourth quarter valued at approximately $158,000. Wells Fargo & Company MN acquired a new position in shares of CeriBell in the fourth quarter valued at $167,000. Rhumbline Advisers acquired a new position in shares of CeriBell in the fourth quarter valued at $320,000. Finally, Norges Bank bought a new position in CeriBell in the fourth quarter worth $422,000.

CeriBell Stock Up 2.2 %

Shares of NASDAQ:CBLL opened at $22.32 on Thursday. The business has a 50-day moving average of $24.52. CeriBell has a fifty-two week low of $18.69 and a fifty-two week high of $32.75.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The company had revenue of $17.20 million during the quarter, compared to analysts’ expectations of $17.06 million. As a group, analysts predict that CeriBell will post -2.46 EPS for the current fiscal year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.